Bristol-Myers Squibb Co vs Wells Fargo & Co — how do they compare? Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B), while Wells Fargo & Co trades at $87.35 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 2× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | WFC | |
|---|---|---|
Market Cap | $129.94B | $264.66B |
Sector | Health | Financials |
52-Week High | $65.89 | $96.40 |
52-Week Low | $42.60 | $73.42 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | 2.29% |
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →